Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alp...
Saved in:
| 主要作者: | |
|---|---|
| 格式: | Thesis |
| 語言: | English |
| 出版: |
2013
|
| 主題: | |
| 在線閱讀: | http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| id |
my-upm-ir.48690 |
|---|---|
| record_format |
uketd_dc |
| spelling |
my-upm-ir.486902016-10-14T08:08:09Z Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities 2013-11 Abd Aziz, Noraini Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alpha subunit of hypoxia inducible factor 1 (HIF-1) is not degraded, the heterodimeric HIF-1 fails to transactivate target genes. HIF-1 and HIF-2 are related hypoxia-inducible transcription factors that are important for survival of hypoxic tumor cells. Most reports have focused on the effects of bortezomib on HIF-1 but not HIF-2 transcriptional activities. In the present study, the effect of bortezomib on HIF-2 activity in cells with different levels of expression of the HIF-1α and HIF-2α subunits, was investigated. Results showed that bortezomib treatment suppressed the transcription and expression of CA9, a HIF-1-specific target gene, but had minimal effects on EPO and GLUT-1, which are the target genes of both HIF-1 and HIF-2. A similar dichotomy of responses was also seen with exogenously-introduced hypoxia response elements of CA9 and EPO. These data led to a conclusion that bortezomib attenuates the transcriptional activity of only HIF-1 but not HIF-2. This novel finding on the lack of inhibitory effect of bortezomib on HIF-2 transcriptional activity will be important in the improvement of design and treatment modalities to enhance the efficacy of this and other proteasomal inhibitor drugs. Protease inhibitors - Therapeutic use Cancer - Chemotherapy 2013-11 Thesis http://psasir.upm.edu.my/id/eprint/48690/ http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf application/pdf en public masters Universiti Putra Malaysia Protease inhibitors - Therapeutic use Cancer - Chemotherapy |
| institution |
Universiti Putra Malaysia |
| collection |
PSAS Institutional Repository |
| language |
English |
| topic |
Protease inhibitors - Therapeutic use Cancer - Chemotherapy |
| spellingShingle |
Protease inhibitors - Therapeutic use Cancer - Chemotherapy Abd Aziz, Noraini Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities |
| description |
Bortezomib is the first proteasomal inhibitor (PI) to be used therapeutically in humans for treating relapse cases of multiple myeloma and mantle cell lymphoma. A proposed
mechanism is that it prevents proteasomal degradation of pro-apoptotic proteins, leading to enhance apoptosis. Although the alpha subunit of hypoxia inducible factor 1 (HIF-1) is not degraded, the heterodimeric HIF-1 fails to transactivate target genes. HIF-1 and HIF-2 are related hypoxia-inducible transcription factors that are important for survival of hypoxic tumor cells. Most reports have focused on the effects of bortezomib on HIF-1 but not HIF-2 transcriptional activities. In the present study, the effect of bortezomib on HIF-2 activity in cells with different levels of expression of the HIF-1α and HIF-2α
subunits, was investigated. Results showed that bortezomib treatment suppressed the transcription and expression of CA9, a HIF-1-specific target gene, but had minimal
effects on EPO and GLUT-1, which are the target genes of both HIF-1 and HIF-2. A similar dichotomy of responses was also seen with exogenously-introduced hypoxia response elements of CA9 and EPO. These data led to a conclusion that bortezomib attenuates the transcriptional activity of only HIF-1 but not HIF-2. This novel finding on the lack of inhibitory effect of bortezomib on HIF-2 transcriptional activity will be important in the improvement of design and treatment modalities to enhance the efficacy of this and other proteasomal inhibitor drugs. |
| format |
Thesis |
| qualification_level |
Master's degree |
| author |
Abd Aziz, Noraini |
| author_facet |
Abd Aziz, Noraini |
| author_sort |
Abd Aziz, Noraini |
| title |
Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities |
| title_short |
Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities |
| title_full |
Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities |
| title_fullStr |
Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities |
| title_full_unstemmed |
Effects of bortezomib on HIF-1 and HIF-2 transcriptional activities |
| title_sort |
effects of bortezomib on hif-1 and hif-2 transcriptional activities |
| granting_institution |
Universiti Putra Malaysia |
| publishDate |
2013 |
| url |
http://psasir.upm.edu.my/id/eprint/48690/1/FBSB%202013%2039R.pdf |
| _version_ |
1747811992592187392 |